RiverGlade Capital (RiverGlade), a healthcare-focused private equity firm, has closed its latest fund, RiverGlade Capital Fund II (Fund II), which was over-subscribed and exceeded both its target size and initial cap with $453 million of total capital commitments.
RiverGlade’s founders have invested in healthcare services together for over 20 years and will continue to remain focused on healthcare investing in the lower middle market by partnering and supporting founders and management teams of exceptional companies that are driving outcomes for patients, providers, payors and the communities they serve.
Fund II is RiverGlade’s second institutional fund, following a $325 million debut fund raised in 2019. Fund II received strong support from RiverGlade’s existing institutional investor base, as well as a select group of new investors.
Capstone Partners acted as placement agent and Kirkland & Ellis LLP acted as legal counsel to RiverGlade.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.